FSFernanda Santana da Silva

Fernanda Santana da Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda Santana da Silva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and laboratory evaluation of patients with visceral leishmaniasis undergoing different therapeutic regimens of liposomal amphotericin B

    by Fernanda Santana da Silva, Elder Andrade Oliveira Filho, Maria Luísa Santos Fernandes, Gabriel Donner Oliveira, Victor Hugo Dantas Guimarães

    Visceral Leishmaniasis (VL) is an infectious disease caused by protozoa of the Leishmania genus and is transmitted to humans by the bite of infected female Lutzomyia sandflies. Several treatment protocols for VL are available, including the utilization of liposomal amphotericin B. Nevertheless, the optimal protocol with the minimal adverse effects remains uncertain. In this context, the present study aims to assess the clinical and laboratory outcomes of patients with VL undergoing two distinct therapeutic regimens of liposomal amphotericin B. A cross-sectional study was conducted to analyze data from the medical records of patients diagnosed with VL between 2015 and 2019 in an endemic area in the northern region of the State of Minas Gerais, Brazil. All patients in the study were predominantly under the age of 10 years, with 70.4% being male (19 cases). In terms of clinical conditions, fever was present in 92.3% of cases, while splenomegaly and hepatomegaly occurred in 100% of patients. No significant differences were observed between the treatment regimens of liposomal amphotericin B at 4 mg (kg day-1)-1 for 5 days and 3 mg (kg day-1)-1 for 7 days. The data suggest that patients who received liposomal amphotericin B for both 5 and 7 days exhibited no clinically or laboratory differences compared to those who utilized liposomal amphotericin B for a five-day duration.


  • Open Access

    American Tegumentary Leishmaniasis in Montes Claros: an epidemiological study

    by Fernanda Santana da Silva, Jefferson Oliveira Silva, Matheus Felipe Ferreira Aguiar, João José Lopes Santos Neto, Riard Heidson Damasceno Porto, Júlia Rodrigues Ortega, Fillipe Mendes Silva, Gustavo Oliva de Sá, Rogério Gonçalves da Rocha, Victor Hugo Dantas Guimarães

    Introduction: American Tegumentary Leishmaniasis (ATL), or kala azar, is a serious chronic disease caused by Leishmania spp. It is an infectious and non-contagious disease that affects both humans and several species of wild and domestic animals, presenting the clinical forms of cutaneous, mucocutaneous and diffuse cutaneous. ATL is classified as a generalized zoonotic disease that has a global impact. It is caused by protozoa of the genus Leishmania and is considered a serious public health problem. Objective: To describe the epidemiological profile of cases found in Montes Claros-MG. Methodology: An epidemiological assessment was performed based on secondary data from SINAN/MS from January 2010 to December 2015. Results: From 2010 to 2015, 286 cases of ATL were registered, with the majority of cases occurring in children under 19 years of age (31.81%) and patients over 59 years (17.83%) had a lower percentage of disease involvement. The first choice drug used by patients was Glucantime (87.06%). The most affected gender was male (52.44%) and most patients had no comorbidities (76.96%). Conclusion: In Montes Claros, Minas Gerais, ATL presented high cases during the research period. In this sense, this study guides the development of new researches that address and monitor the spread of the disease by monitoring urban areas concomitantly with the capture of animals for the presence of the parasite, thus assisting in public health decision-making in controlling the disease.

  • Open Access

    Epidemiological aspects of visceral leishmaniasis in the municipality of Montes Claros-MG

    by Fernanda Santana da Silva, Jefferson Oliveira Silva, Matheus Felipe Ferreira Aguiar, João José Lopes dos Santos Neto, Rogério Gonçalves da Rocha, Victor Hugo Dantas Guimarães

    Visceral leishmaniasis (VL), also known as 'calazar', is a serious chronic disease caused by Leishmania species from Leishmania (Leishmania) donovani complex, which the disease is characterized by abdominal swelling (hepatosplenomegaly) and may evolve to death in extreme cases. In this sense, the aim of our study was to assess the epidemiological profile of the cases found in Montes Claros (Minas Gerais state). A retrospective or cross-sectional study was carried out using secondary data provided by Health Information System (SINAN/HM) of Brazil from January 2010 to February 2020. Our data has shown that VL is an endemic disease in Montes Claros region, with 413 VL cases reported, 62.00% (252) male, average age +/- standard deviation (years), and 93.46% (386) lived in Montes Claros city. The presence of comorbidities was observed in 13.70% (54) of the patients and in 7.26% (30). As for the evolution of the disease, 246 (59.56%) were cured, 30 (7.26%) died due to VL. Between 2010 and 2015, Glucantime (R) stands out, in which 46 (11.13%) patients used the drug, followed by common Amphotericin B 24 (13.48%) and liposomal Amphotericin B 38 (21.34%). In the period between 2016 and 2020, the most prevalent drug was liposomal Amphotericin B, with 71 (29.83%) patients using it, followed by Glucantime (R) 45 (18.9%). The condition evolved to death. We conclude that Montes Claros is still an endemic area for VL with an increased number of cases over time and a noticeable shift in patient profile towards children and young people. Joint efforts from different areas of scientific knowledge and public health services are needed to improve the effectiveness of visceral leishmaniasis surveillance and control actions. The population can contribute to this process of disease prevention and control, through educational actions in health and the environment.